Estimating the cost-effectiveness of nutrition supplementation for malnourished, HIV-infected adults starting antiretroviral therapy in a resource-constrained setting

Cost Effectiveness and Resource Allocation

Jeffrey S Stringer⁵  Douglas Heimburger⁴  Benjamin H Chi⁵  Mark J Giganti³  Elliot Marseille²  John R Koethe¹ 

[1] Division of Infectious Diseases, Vanderbilt University School of Medicine, 215 Light Hall, Nashville, TN 37232, USA;Health Strategies International, 555 59th Street, Oakland, CA 94609, USA;Department of Biostatistics, Vanderbilt University School of Medicine, 215 Light Hall, Nashville, TN 37232, USA;Vanderbilt Institute for Global Health, 2525 West End Ave., Nashville, TN 37203, USA;Department of Obstetrics and Gynecology, UNC Global Women’s Health, University of North Carolina at Chapel Hill School of Medicine, 3009 Old Clinic Building CB #7570, Chapel Hill, NC 27599-7570, USA

关键词: Africa;    Zambia;    Malnutrition;    Nutrition;    Antiretroviral therapy;    HIV;   

Others  :  809694
DOI  :  10.1186/1478-7547-12-10

 received in 2013-08-20, accepted in 2014-04-17,  发布年份 2014

【 摘 要 】

Background

Low body mass index (BMI) individuals starting antiretroviral therapy (ART) for HIV infection in sub-Saharan Africa have high rates of death and loss to follow-up in the first 6 months of treatment. Nutritional supplementation may improve health outcomes in this population, but the anticipated benefit of any intervention should be commensurate with the cost given resource limitations and the need to expand access to ART in the region.

Methods

We used Markov models incorporating historical data and program-wide estimates of treatment costs and health benefits from the Zambian national ART program to estimate the improvements in 6-month survival and program retention among malnourished adults necessary for a combined nutrition support and ART treatment program to maintain cost-effectiveness parity with ART treatment alone. Patients were stratified according to World Health Organization criteria for severe (BMI <16.0 kg/m²), moderate (16.00-16.99 kg/m²), and mild (17.00-18.49 kg/m²) malnutrition categories.

Results

19,247 patients contributed data between May 2004 and October 2010. Quarterly survival and retention were lowest in the BMI <16.0 kg/m² category compared to higher BMI levels, and there was less variation in both measures across BMI strata after 180 days. ART treatment was estimated to cost $556 per year and averted 7.3 disability-adjusted life years. To maintain cost-effectiveness parity with ART alone, a supplement needed to cost $10.99 per quarter and confer a 20% reduction in both 6-month mortality and loss to follow-up among BMI <16.0 kg/m² patients. Among BMI 17.00-18.49 kg/m² patients, supplement costs accompanying a 20% reduction in mortality and loss to follow-up could not exceed $5.18 per quarter. In sensitivity analyses, the maximum permitted supplement cost increased if the ART program cost rose, and fell if patients classified as lost to follow-up at 6 months subsequently returned to care.

Conclusions

Low BMI adults starting ART in sub-Saharan Africa are at high risk of early mortality and loss to follow-up. The expense of providing nutrition supplementation would require only modest improvements in survival and program retention to be cost-effective for the most severely malnourished individuals starting ART, but interventions are unlikely to be cost-effective among those in higher BMI strata.

【 授权许可】

   
2014 Koethe et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Food and Agricultural Organzation of the United Nations: The State of Food Insecurity in the World 2008. In The State of Food Insecurity in the World 2008. FAO; 2008. [ftp://ftp.fao.org/docrep/fao/011/i0291e/i0291e00.pdf webcite]
• [2]World Health Organisation/Joint United Nations Programme on HIV/AIDS: Towards universal access, scaling up priority HIV/AIDS interventions in the health sector progress report 2009. World Health Organisation; 2009. [http://www.who.int/hiv/pub/2009progressreport/en/ webcite]
• [3]Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, Mtonga V, Reid S, Cantrell RA, Bulterys M, Saag MS, Marlink RB, Mwinga A, Ellerbrock TV, Sinkala M: Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006, 296:782-793.
• [4]Gupta A, Nadkarni G, Yang WT, Chandrasekhar A, Gupte N, Bisson GP, Hosseinipour M, Gummadi N: Early Mortality in Adults Initiating Antiretroviral Therapy (ART) in Low- and Middle-Income Countries (LMIC): A Systematic Review and Meta-Analysis. PLoS One 2011, 6:e28691.
• [5]Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, Makombe S, Harries AD: Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 2006, 20:2355-2360.
• [6]Johannessen A, Naman E, Ngowi BJ, Sandvik L, Matee MI, Aglen HE, Gundersen SG, Bruun JN: Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis 2008, 8:52. BioMed Central Full Text
• [7]Koethe JR, Lukusa A, Giganti MJ, Chi BH, Nyirenda CK, Limbada MI, Banda Y, Stringer JS: Association between weight gain and clinical outcomes among malnourished adults initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr 2010, 53:507-513.
• [8]Madec Y, Szumilin E, Genevier C, Ferradini L, Balkan S, Pujades M, Fontanet A: Weight gain at 3 months of antiretroviral therapy is strongly associated with survival: evidence from two developing countries. AIDS 2009, 27:853-861.
• [9]Liu E, Spiegelman D, Semu H, Hawkins C, Chalamilla G, Aveika A, Nyamsangia S, Mehta S, Mtasiwa D, Fawzi W: Nutritional Status and Mortality Among HIV-Infected Patients Receiving Antiretroviral Therapy in Tanzania. J Infect Dis 2011, 204:282-290.
• [10]Cantrell RA, Sinkala M, Megazinni K, Lawson-Marriott S, Washington S, Chi BH, Tambatamba-Chapula B, Levy J, Stringer EM, Mulenga L, Stringer JS: A pilot study of food supplementation to improve adherence to antiretroviral therapy among food-insecure adults in Lusaka, Zambia. J Acquir Immune Defic Syndr 2008, 49:190-195.
• [11]Koethe JR, Limbada MI, Giganti MJ, Nyirenda CK, Mulenga L, Wester CW, Chi BH, Stringer JS: Early immunologic response and subsequent survival among malnourished adults receiving antiretroviral therapy in Urban Zambia. AIDS 2010, 24:2117-2121.
• [12]Ndekha MJ, van Oosterhout JJ, Zijlstra EE, Manary M, Saloojee H, Manary MJ: Supplementary feeding with either ready-to-use fortified spread or corn-soy blend in wasted adults starting antiretroviral therapy in Malawi: randomised, investigator blinded, controlled trial. BMJ 2009, 338:b1867.
• [13]Rawat R, Kadiyala S, McNamara PE: The impact of food assistance on weight gain and disease progression among HIV-infected individuals accessing AIDS care and treatment services in Uganda. BMC Public Health 2010, 10:316. BioMed Central Full Text
• [14]Ivers LC, Chang Y, Gregory Jerome J, Freedberg KA: Food assistance is associated with improved body mass index, food security and attendance at clinic in an HIV program in central Haiti: a prospective observational cohort study. AIDS Res Ther 2010, 7:33. BioMed Central Full Text
• [15]Tirivayi N, Koethe JR, Groot W: Clinic-Based Food Assistance is Associated with Increased Medication Adherence among HIV-Infected Adults on Long-Term Antiretroviral Therapy in Zambia. J AIDS Clin Res 2012, 3:171.
• [16]Marseille E, Giganti MJ, Mwango A, Chisembele-Taylor A, Mulenga L, Over M, Kahn JG, Stringer JS: Taking ART to Scale: Determinants of the Cost and Cost-Effectiveness of Antiretroviral Therapy in 45 Clinical Sites in Zambia. PLoS One 2012, 7:e51993.
• [17]Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM, Chi BH, Sinkala M, Kankasa C, Wilson CM, Wilfert CM, Mwango A, Levy J, Abrams EJ, Bulterys M, Stringer JS: Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 2007, 298:1888-1899.
• [18]Bratt JH, Torpey K, Kabaso M, Gondwe Y: Costs of HIV/AIDS outpatient services delivered through Zambian public health facilities. Trop Med Int Health 2011, 16:110-118.
• [19]Marseille E, Kahn JG, Pitter C, Bunnell R, Epalatai W, Jawe E, Were W, Mermin J: The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda. Appl Health Econ Health Policy 2009, 7:229-243.
• [20]Galarraga O, Wirtz VJ, Figueroa-Lara A, Santa-Ana-Tellez Y, Coulibaly I, Viisainen K, Medina-Lara A, Korenromp EL: Unit costs for delivery of antiretroviral treatment and prevention of mother-to-child transmission of HIV: a systematic review for low- and middle-income countries. Pharmacoeconomics 2011, 29:579-599.
• [21]Beck EJ, Harling G, Gerbase S, DeLay P: The cost of treatment and care for people living with HIV infection: implications of published studies, 1999-2008. Curr Opin HIV AIDS 2010, 5:215-224.
• [22]United Nations Administrative Committee on Coordination Sub-Committee on Nutrition: Fourth Report on the World Nutrition Situation. Geneva: United Nations; 2000.
• [23]Murray CJ: Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ 1994, 72:429-445.
• [24]Mermin J, Were W, Ekwaru JP, Moore D, Downing R, Behumbiize P, Lule JR, Coutinho A, Tappero J, Bunnell R: Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet 2008, 371:752-759.
• [25]Marseille E, Saba J, Muyingo S, Kahn JG: The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda. AIDS 2006, 20:907-914.
• [26]United States Agency for International Development: Food Commodity Fact Sheets. [http://www.usaid.gov/what-we-do/agriculture-and-food-security/food-assistance/resources/implementation-tools/commodity webcite]
• [27]Nutriset: Plumpy’nut product information. [http://www.nutriset.fr webcite]
• [28]Briend A: Highly nutrient-dense spreads: a new approach to delivering multiple micronutrients to high-risk groups. Br J Nutr 2001, 85(Suppl 2):S175-S179.
• [29]Food and Agriculture Organisation of the United Nations: Historical Commodity Prices. [http://www.fao.org/economic/est/prices webcite]
• [30]Melchior JC, Salmon D, Rigaud D, Leport C, Bouvet E, Detruchis P, Vilde JL, Vachon F, Coulaud JP, Apfelbaum M: Resting energy expenditure is increased in stable, malnourished HIV-infected patients. Am J Clin Nutr 1991, 53:437-441.
• [31]World Food Programme United Nations High Commissioner for Refugees: Guidelines for Estimating Food and Nutrition Requirements. Rome: WFP; 1997.
• [32]Rosen S, Long L: How Much Does it Cost to Provide Antiretroviral Therapy for HIV/AIDS in Africa?. Boston: Center for Health and Development Boston University; 2006.
• [33]Brinkhof MW, Boulle A, Weigel R, Messou E, Mathers C, Orrell C, Dabis F, Pascoe M, Egger M: Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med 2009, 6:e1000066.
• [34]Grinspoon S, Corcoran C, Rosenthal D, Stanley T, Parlman K, Costello M, Treat M, Davis S, Burrows B, Basgoz N, Klibanski A: Quantitative assessment of cross-sectional muscle area, functional status, and muscle strength in men with the acquired immunodeficiency syndrome wasting syndrome. J Clin Endocrinol Metab 1999, 84:201-206.
• [35]Yarasheski KE, Zachwieja JJ, Gischler J, Crowley J, Horgan MM, Powderly WG: Increased plasma gln and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting. Am J Physiol 1998, 275:E577-E583.
• [36]Macallan DC, McNurlan MA, Milne E, Calder AG, Garlick PJ, Griffin GE: Whole-body protein turnover from leucine kinetics and the response to nutrition in human immunodeficiency virus infection. Am J Clin Nutr 1995, 61:818-826.
• [37]Heimburger DC, Koethe JR, Nyirenda C, Bosire C, Chiasera JM, Blevins M, Munoz AJ, Shepherd BE, Potter D, Zulu I, Chisembele-Taylor A, Chi BH, Stringer JS, Kabagambe EK: Serum phosphate predicts early mortality in adults starting antiretroviral therapy in Lusaka. Zambia: a prospective cohort study. PLoS One 2010, 5:e10687.
• [38]Mathers CD, Bernard C, Iburg KM, Inoue M, Fat DM, Shibuya K, Stein C, Tomijima N, Xu H: Global Burden of Disease in 2002:data sources, methods and results. World Health Organization; 2004. [http://www.who.int/healthinfo/paper54.pdf webcite]
• [39]Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, Begum N, Shah R, Karyana M, Kosen S, Farje MR, Moncada G, Dutta A, Sazawal S, Dyer A, Seiler J, Aboyans V, Baker L, Baxter A, Benjamin EJ, Bhalla K, Bin Abdulhak A, Blyth F, Bourne R, Braithwaite T, Brooks P, Brugha TS, Bryan-Hancock C, Buchbinder R, Burney P, et al.: Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012, 380:2129-2143.